<DOC>
	<DOCNO>NCT00308204</DOCNO>
	<brief_summary>The purpose study investigate efficacy Raptiva ( efalizumab ) treatment discoid lupus erythematosus ( DLE ) . Discoid lupus erythematosus chronic disorder , may lead permanent progressive loss hair . Lupus condition chronic inflammation cause autoimmune disease . Autoimmune diseases illness occur body 's tissue attack immune system . The immune system complex system within body design fight infectious agent , example , bacteria , foreign invader . One mechanism immune system use fight infection production antibody . Patients lupus produce abnormal antibody blood target tissue within body rather foreign infectious agent . Lupus cause disease skin , heart , lung , kidney , joint , nervous system . When skin involve , condition call discoid lupus erythematosus ( DLE ) . Raptiva ( efalizumab ) humanize immunoglobulin ( protein extract blood fight infection-sometimes call `` antibody '' ) , target immune cell activate inflammation . Raptiva approve use management psoriasis dose 1mg/kg , approve treatment DLE .</brief_summary>
	<brief_title>Discoid Lupus Erythematosus Scalp Trial Biologic Therapy With Raptiva</brief_title>
	<detailed_description>This open label study subject give medication Raptiva ( efalizumab ) teach self-inject dermatology nurse research doctor . The subject administer 0.7mg/kg week one 1mg/kg week thereafter week 24 . If subject feel uncomfortable self-administering injection , subject may identify caregiver administer injection . He teach administer injection dermatology nurse research doctor .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Lupus Erythematosus , Discoid</mesh_term>
	<criteria>adult discoid lupus erythematosus active area disease involve least 10 % scalp , confirm biopsy , bacterial fungal culture negative . ability provide write informed consent comply study assessment full duration study . adult 18 70 year age . female childbearing potential , negative pregnancy test commitment use two form effective contraception ( birth control ) duration study necessary . nonsterile male , commitment use two form effective contraception ( birth control ) duration study necessary . Platelets &gt; 100,000 subject know hypersensitivity Raptiva ( efalizumab ) component pregnant lactating woman patient receive immunosuppressive agent ( allow 30 day 5 halflive period Day 0 , whichever long ) . prior enrollment study condition investigator believe would pose significant hazard subject investigational therapy initiate . participation another simultaneous medical investigation trial history malignancy last 10 year . sign symptom systemic lupus erythematosus . history active tuberculosis currently undergo treatment tuberculosis . A purified protein derivative ( PPD ) test chest xray perform screening visit . Patients positive PPD test chest xray exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>discoid lupus</keyword>
	<keyword>lupus</keyword>
	<keyword>discoid lupus erythematosus</keyword>
	<keyword>lupus scalp</keyword>
</DOC>